Epidemiological profile and progress toward rubella elimination in China. 10 years after nationwide introduction of rubella vaccine☆
Introduction
Though acquired rubella is usually a benign disease of children and young adults, rubella virus is a highly teratogenic pathogen, particularly when infection occurs during the first 16 weeks of pregnancy. In early-pregnancy infections, the developing organs of the fetus are often damaged, resulting in miscarriage, stillbirth, or an infant born with birth defects - congenital rubella syndrome (CRS). The goal of rubella vaccination programs is prevention of the intrauterine infection that causes CRS [1], and the only way to ensure that CRS does not occur is to eliminate the possibility of exposure to rubella virus. To this end, at the World Health Assembly (WHA) in May 2012, all 194 Member States endorsed the target of eliminating rubella in five of the six WHO Regions by 2020 as part of the Global Vaccine Action Plan (GVAP) of the Decade of Vaccines [2]. Feasibility has been shown by the elimination of endemic transmission of rubella virus in the WHO Region of the Americas, declared in 2009 [3]. In October 2017, the WHO Western Pacific Regional Committee passed unanimously a resolution that “urged that all Member States in the Region aim to eliminate rubella as soon as possible [4].”
China, with a mainland population of more than 1.38 billion and an area of 9.6 million km2, is the largest country in WHO’s Western Pacific Region. Rubella-containing vaccine (RCV) was licensed and made available in China in 1993 and was introduced nationwide into the Expanded Immunization Program (EPI) 10 years ago, in 2008. Given the interest in rubella elimination by WHO and ministries of health, we report a study in China about rubella vaccine use and coverage, the epidemiological profile of rubella, and progress and challenges of elimination of rubella from 2005 through 2017. We discuss implications of our findings and make recommendations to help hasten elimination of rubella and prevention of CRS outbreaks in China.
Section snippets
Study setting
The study is set in mainland of the People’s Republic of China, not including Hong Kong Special Administrative Region, Macao Special Administrative Region, and Taiwan.
Rubella vaccines in China
There are 3 types of rubella containing vaccine (RCV) available in China - standalone rubella vaccine (RV), measles-rubella combined vaccine (MR), and measles-mumps-rubella combined vaccine (MMR). China has used two rubella vaccine virus strains - an imported RA27 strain from international manufacturers and a domestic BRD-II
Rubella vaccine supply
From 2008 to 2016 in China, the annual number of doses of RCVs released to EPI and distributed increased from 40.0 million in 2008 to 62.6 million in 2016 with lowest number of doses occurring in 2009, at 20.8 million. In 2015 there was a decrease in vaccine production because of a GMP certification challenge. On average, more than 50 million doses of RCVs were released each year into China’s EPI system, which serves an annual birth cohort of 16 million live births (Fig. 1).
Rubella routine immunization coverage
Routine RCV1
Discussion
Incorporating rubella into the China EPI system in 2008 was an important step toward control and elimination of rubella and prevention of CRS. We have shown that the incidence of rubella has steadily decreased from 91.0 per million in 2008 down to 1.16 per million in 2017. Decreases occurred in all age groups, including the vaccine-targeted age groups of children 2 to 9 years and non-targeted age groups, showing direct and indirect protection from rubella. The impact on incidence was documented
Conflicts of interest
The authors declare that they have no conflict of interest.
Acknowledgements
The authors give special thanks to Dr. Lance E Rodewald (WHO China Representative Office) for his help in revising and polishing this manuscript and Dr. Walter Orenstein (Emory University) for his helpful comments on our manuscript.
Author Contributions
Chao Ma, Lixin Hao, Ning Wen conceived of the study, contributed to its design, analyzed and interpreted of data; Chunxiang Fan, Hong Yang contributed to study design, interpreted data, reviewed results, provided references to published ones; Huaqing Wang, Zundong Yin, Zijian Feng, Weizhong Yang contributed to study design, reviewed results, provided data and revised the article; Qiru Su conceived of the study, contributed to its design, analyzed and interpretation of data, and drafted the
References (20)
- et al.
A rubella outbreak investigation and BRD-II strain rubella vaccine effectiveness study, Harbin city, Heilongjiang province, China, 2010–2011
Vaccine
(2013) - et al.
Rubella Lancet
(2015) - et al.
Seroprevalence of rubella in female migrant factory workers in Shenzhen
China Vac
(2010) - et al.
Rubella virus immunization status in preconception period among Chinese women of reproductive age: a nation-wide, cross-sectional study
Vaccine
(2017) - et al.
Effectiveness of Rubella vaccine in a rubella outbreak in Guangzhou city, China, 2014
Vaccine
(2015) - Rubella vaccines: WHO position paper. Wkly Epidemiol Rec. 2011; 86(29):...
- et al.
Progress in Rubella and Congenital Rubella Syndrome Control and Elimination - Worldwide, 2000–2016
MMWR Morb Mortal Wkly Rep
(2017) - et al.
Elimination of endemic measles, rubella, and congenital rubella syndrome from the Western hemisphere: the US experience
JAMA Pediatr
(2014) - World Health Organization. Measles and rubella elimination resolution....
- et al.
Rubella epidemics and genotypic distribution of the rubella virus in Shandong Province, China, in 1999–2010
PLoS One
(2012)
Cited by (26)
Molecular surveillance of rubella virus in Beijing, China during 2010–2021: Progress and challenges in rubella elimination
2022, VaccineCitation Excerpt :The 62 representative RV sequences from Beijing during 2012–2020 have been submitted to the GenBank database, and the accession numbers are OP242875- OP242897 for lineage 1E-L1, OP242858-OP242874 for lineage 1E-L2, OP242836 and OP242844- OP242858 for lineage 2B-L1, and OP242837- OP242843 for lineage 2B-L2c strains. Rubella-containing vaccines (RCVs) were formally introduced into the routine immunization program in China in 2008 [11]. Based on the two-dose national immunization strategy for rubella (8 months and 18 months), another booster dose of RCV at the age of 6 years was also included in the Beijing immunization program; thus, three-dose immunization policy (8 months, 18 months, and 6 years) has been implemented in Beijing since 2009.
Accelerate the elimination of rubella through supplementary immunisation activities in China
2021, The Lancet Infectious DiseasesAssessing the burden of congenital rubella syndrome in China and evaluating mitigation strategies: a metapopulation modelling study
2021, The Lancet Infectious DiseasesCitation Excerpt :Nor was a campaign to catch up older children conducted. Nonetheless, as rubella-containing vaccines became available, administrative estimates of routine uptake (ie, quotients of doses administered and target population size) increased rapidly.8 Rubella has been a notifiable disease in China since 1990, but incidence was monitored initially through sentinel surveillance in 145 prefectures,9 a population of 11 million people (approximately 1% of the population at that time).
Epidemiology of rubella and its viral genetic characterization in China, 2021-2022
2024, Chinese Journal of Experimental and Clinical VirologySeroepidemiology study of rubella virus antibodies among neonates and pregnant women at hospitals in Henan province, China
2023, Journal of Medical Virology
- ☆
This study was funded in part by the World Health Organization Cooperation Project “Developing a mathematical model of measles and rubella elimination to refine the immunization strategies in China”.